All News
RheumNow Podcast – Uppers and Downers
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com.
Read ArticleDual IL-17 Targeting is Effective but has More Candidiasis
Bimekizumab (BIM) is a monoclonal antibody that targets both interleukin-17A and interleukin-17F, which as a biologic target has worked well in the management of psoriatic disease. The current issue of the NEJM has two reports wherein BIM was shown to be more effective than secukinumab and adalimumab in treating patients with moderate-to-severe plaque psoriasis; however, safety concerns arise.
Read ArticleDr. John Cush RheumNow ( View Tweet)
ACR Promotes New COVID-19 Vaccine Clinical Guidance for Rheumatic Patients
The American College of Rheumatology has published a draft guidance on the use of COVID-19 vaccination in rheumatic disease and musculoskeletal disease patients, based on the efforts of the North American Task force. The document provides guidance to rheumatology providers on the use of the COVID-19 vaccine and the associated management of RMD patients around the time of vaccination. Here is a summary of the recommendations.
Read ArticleSpA: Etiology to Diagnosis to Treatment - An Abstract Roundup
Here's a review of ten abstracts and presentations on spondyloarthritis encompassing a wide range of topics from etiology to diagnosis to treatment.
Read ArticleEvolution of GCA Treatments - More to Come
The field of Rheumatology is an ever-nascent field with an incredible expansion in our therapeutic armamentarium over the past half century. An example of such advancement is easily appreciated when reflecting on the innovative treatment approach to Giant Cell Arteri
Read Article1yr results using anti-IL-23 Guselkumab shows the same ACR 20/50/70 responses regardless of prior TNF inhibitor failure. #ACR20 #Abstr#1344 https://t.co/OvgJ53wwmU https://t.co/JdajDONWap
ACR20 Best Abstracts - Day 2
The RheumNow faculty reporters have been scouring and reporting on the best abstracts from the ACR. Here is a sampling of their choice abstract presentations reported during ACR 2020 Day 2 (#ACRbest).
Read ArticleComparative Efficacy of Guselkumab in Patients with Psoriatic Arthritis: Results from Systematic Literature Review and Network Meta-Analysis https://t.co/hgPDtFRxer #PsA #Guselkumab
Peter Nash drpnash ( View Tweet)
Industry Abstract Previews - ACR2020
Each pharmaceutical company has spent months and years preparing to present and highlight their featured clinical trials and abstracts at ACR 2020. This is our selection of their best studies for you to review and evaluate as part of your to-do list.
Read ArticleDISCOVER-2 (52 wk study) Guselkumab 100mg q4wk and q8wk for tx of PsA 1️⃣Sustained responses in: ACR20/50/70, PASI90/100, HAQ-DI, MDA/VLDA, QoL 2️⃣Improvement enthesitis/dactylitis 3️⃣No increase rate of serious infection @RheumNow #ACR20 Abs#0506 https://t.co/7MXYTucVZ9
Links:
Dr. John Cush RheumNow ( View Tweet)
IL-12 and IL-23 Promote Giant Cell Arteritis
It has been postulated that TH1 and TH17 pathways are implicated in the pathogenesis of giant cell arteritis (GCA); this is supported by new research showing that interleukin 12 (IL-12) and interleukin 23 (IL-23) may stimulate inflammatory and proliferative pathways relevant to the path
Read ArticleIL-23 Inhibitor Fails in Ankylosing Spondylitis
A study of the IL-23 risankizumab in active ankylosing spondylitis (AS) patients failed to show efficacy and did not meet primary efficacy endpoints in a 6-month trial.
Read Article